Is gene testing required before starting nivolumab?
No, gene testing is not necessary before nivolumab (Opdivo) treatment. Nivolumab, a PD-1 inhibitor, is approved for use across multiple cancers like melanoma, lung cancer, and renal cell carcinoma without mandatory genetic or biomarker testing as a prerequisite for initiation.[1][2] Labeling and guidelines from the FDA and NCCN emphasize patient selection based on tumor type, stage, and performance status, not germline or tumor genetic profiling.
When is PD-L1 testing used instead?
PD-L1 expression testing on tumor cells guides treatment in some cases but is not required to start nivolumab. For example:
- In non-small cell lung cancer (NSCLC), it's recommended for first-line use with platinum chemotherapy if PD-L1 is under 50%, but high PD-L1 (>=50%) favors pembrolizumab monotherapy—nivolumab still proceeds without it in later lines.[3]
- No PD-L1 test is needed for melanoma or Hodgkin lymphoma approvals.
Combination regimens (e.g., with ipilimumab) also skip it universally.[1]
What about other biomarkers like tumor mutation burden or MSI?
Testing for tumor mutational burden (TMB) or microsatellite instability (MSI-H/dMMR) is optional and not required for nivolumab alone:
- FDA approval for high TMB (>=10 mut/Mb) or MSI-H covers nivolumab in solid tumors, but these apply to broad pan-tumor indications, not routine pre-treatment screening.[4]
- Most standard approvals (e.g., adjuvant melanoma) ignore these entirely.
| Indication | PD-L1 Test? | TMB/MSI Test? | Gene Test? |
|------------|-------------|---------------|------------|
| Melanoma | No | No | No |
| NSCLC | Sometimes | No | No |
| RCC | No | No | No |
| MSI-H | No | Recommended | No |
Why might doctors order genetic tests anyway?
Physicians sometimes test for:
- EGFR/ALK/ROS1 mutations in NSCLC to rule out targeted therapies first—nivolumab is not first-line if these are present.[3]
- BRAF in melanoma, where targeted inhibitors precede immunotherapy.
These are pathway-specific, not nivolumab-specific, and guidelines like NCCN flag them as preferred over immunotherapy in positive cases.[5]
Risks of skipping tests and patient concerns
No gene tests mean faster access, but immunotherapy risks immune-related adverse events (e.g., colitis, pneumonitis) in 20-30% of patients regardless of genetics.[2] Patients with autoimmune diseases or specific variants (e.g., JAK2) may need caution, but no pre-treatment genetic mandate exists. Consult oncology guidelines for individual risks.
[1]: [FDA Opdivo Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf)
[2]: NCCN Guidelines: Immunotherapy
[3]: NCCN NSCLC Guidelines v.2024
[4]: FDA TMB Approval
[5]: NCCN Melanoma Guidelines